Genotype | Placebo | Â | ET | Â | EPT | Â | Â | |||
---|---|---|---|---|---|---|---|---|---|---|
 | Mean (N) | SEM | P* | Mean (N) | SEM | P | Mean (N) | SEM | P | P †|
COMT Val158Met | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Val/Val | - 0.1 (30) | 1.4 | Ref. | 3.7 (30) | 1.4 | Ref. | 8.0 (12) | 2.3 | Ref. | Â |
Val/Met | 0.5 (45) | 1.2 | 0.74 | 4.3 (48) | 1.1 | 0.72 | 6.2 (19) | 1.9 | 0.54 | Â |
Met/Met | - 0.6 (19) | 1.8 | 0.82 | 6.0 (25) | 1.6 | 0.27 | 9.8 (3) | 4.5 | 0.72 | 0.77 |
CYP1B1 Val432Leu | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Val/Val | - 0.7 (15) | 1.9 | Ref. | 4.7 (23) | 1.6 | Ref. | 6.9 (7) | 2.9 | Ref. | Â |
Leu/Val | - 0.01 (42) | 1.2 | 0.75 | 5.8 (44) | 1.2 | 0.57 | 1.3 (13) | 2.1 | 0.11 | Â |
Leu/Leu | 0.9 (36) | 1.2 | 0.47 | 3.6 (37) | 1.2 | 0.61 | 14.5 (13) | 2.1 | 0.03 | 0.0004 |
UGT1A1 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
<7/<7 TA repeats | 0.3 (37) | 1.3 | Ref. | 5.7 (50) | 1.1 | Ref. | 7.1 (18) | 1.9 | Ref. | Â |
<7/≥ 7 TA repeats | - 0.5 (43) | 1.2 | 0.60 | 3.3 (39) | 1.3 | 0.15 | 8.7 (12) | 2.3 | 0.57 |  |
≥ 7/≥ 7 TA repeats | 0.6 (14) | 2.1 | 0.92 | 4.4 (14) | 2.1 | 0.58 | 5.4(3) | 4.6 | 0.74 | 0.77 |
AKR1C4 L311V | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Leu/Leu | - 0.3 (72) | 0.9 | Ref. | 4.3 (79) | 0.8 | Ref. | 4.0 (25) | 1.6 | Ref. | Â |
Leu/Val | 1.5 (21) | 1.6 | 0.30 | 5.5 (25) | 1.5 | 0.47 | 16.7 (7) | 2.8 | 0.0001 | Â |
Val/Val | 0.6 (1) | Â | 0.90 | (0) | Â | Â | 29.3 (1) | Â | 0.0007 | 0.001 |